GSK Shelves Cough Drug Acquired in $2B Deal, Says 'Not Good Enough to Compete'

GSK has shelved a cough drug it acquired in a $2 billion deal, citing the medicine's inability to compete in the market, while the company's global vaccine sales have surged.

GSK has shelved a cough drug it acquired in a $2 billion deal, marking a significant setback for the pharmaceutical giant's respiratory portfolio. The drug, which was acquired as part of a broader push into respiratory treatments, was deemed "not good enough to compete" in the competitive cough market.

"We have made the difficult decision to discontinue the development of this asset. It is not good enough to compete with the current standard of care," said a GSK spokesperson.

The decision comes as GSK has faced increasing competition in the respiratory space, with rivals such as AstraZeneca and Novartis developing more advanced treatments for chronic cough and related conditions.

"This is a significant setback for GSK's respiratory portfolio," said an industry analyst.

"The company had high hopes for this drug, but the data simply did not support its continued development."

Despite the setback, GSK's vaccine business has been performing strongly, with global vaccine sales rising 18 per cent to $6.2 billion, driven by demand for its respiratory syncytial virus (RSV) and shingles vaccines.

"Our vaccine portfolio continues to deliver strong growth, and we remain committed to investing in this area," the spokesperson added.

Here is the question this move raises. GSK has shelved a cough drug acquired in a $2 billion deal, while its vaccine business surges. When pharmaceutical companies face setbacks, does the strength of their vaccine portfolios provide a cushion against failure?

As GSK shelves its cough drug acquired in a $2 billion deal, The Silicon Review asks a final question. When a $2 billion acquisition is shelved, what does it take for a pharmaceutical company to cut its losses and move on?

FAQ:

Q: Why did GSK shelve the cough drug?
A: GSK shelved the drug because it was deemed "not good enough to compete" with existing treatments in the market.

Q: How much did GSK pay for the cough drug?
A: GSK acquired the cough drug as part of a $2 billion deal.

Q: Has GSK's vaccine business been performing well?
A: Yes, GSK's vaccine sales rose 18% to $6.2 billion, driven by demand for its RSV and shingles vaccines.

Q: Is this the first setback for GSK's respiratory portfolio?
A: GSK has faced increasing competition in the respiratory space, with rivals such as AstraZeneca and Novartis developing more advanced treatments.